TARIS Biomedical LLC

CG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data

Johnson & Johnson 's 2019 acquisition of privately held TARIS Biomedical LLC for an undisclosed sum is looking like a canny move after new data from early trials of its lead product, TAR-200, sugges

One of Johnson & Johnson ’s high-profile pipeline drugs, TAR-200, has missed in a Phase III trial in patients with muscle-invasive bladder cancer (MIBC), but the company said the drug-device technolo

Johnson & Johnson is not ruling out being a late entrant into the obesity space. During an appearance at the Morgan Stanley Healthcare Conference on 4 September, CEO Joaquin Duato said the company is